Labcorp Holdings Inc.
LH
Positions held
Your positionsLH isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Labcorp is well-positioned in the diagnostics industry, benefiting from a growing demand for healthcare services and innovative testing solutions.
- In Q2 2026, Labcorp reported a revenue increase of 5% compared to the prior quarter, reaching $3.7 billion.
- The company's gross margin improved to 29.8% in Q2 2026, up from 28.7% in the previous quarter.
- Despite its strengths, Labcorp faces challenges with a high debt-to-equity ratio of 79.124, which may impact financial stability.
- The company's operating margin has been relatively low, at 10.87% for the year 2025, indicating potential inefficiencies.
- Labcorp's stock has a trailing P/E ratio of 25.53, suggesting it may be overvalued compared to its earnings growth potential.
Fundamentals
| Market cap | $25.48B | Enterprise value | $32.18B | Trailing P/E | 25.99 | Forward P/E | 15.86 |
| PEG | 1.22 | Price / book | 2.95 | Beta | 0.85 | Dividend yield | 0.92% |
| Revenue growth | 5.8% | Earnings growth | 28.2% | Gross margin | 28.9% | Operating margin | 12.2% |
| Profit margin | 7.0% | ROE | 11.7% | ROA | 5.5% | Debt / equity | 0.79 |
| Current ratio | 1.80 | Free cash flow | $892.05M | Analyst recommendation | buy | Mean target | $344.19 |
| 52w high | $341.80 | 52w low | $244.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.7B | $3.5B | $3.5B | $3.6B | $3.5B | — |
| Op margin | 12.2% | 10.9% | 10.9% | 11.3% | 11.3% | — |
| Net income | $299M | $278M | $165M | $261M | $238M | — |
| Gross margin | 29.8% | 28.7% | 28.2% | 28.8% | 29.7% | — |
| Gross profit | $1.1B | $1.0B | $993M | $1.0B | $1.0B | — |
| Operating income | $457M | $387M | $382M | $403M | $399M | — |
- Revenue +5% vs prior quarter ($3.7B vs $3.5B).
- Gross margin 29.8% (was 28.7% prior quarter).
- Operating margin expanded to 12.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $14.0B | $13.0B | $12.2B | $11.9B |
| Op margin | 10.9% | 8.7% | 9.2% | 14.8% |
| Net income | $877M | $746M | $418M | $1.3B |
| Gross margin | 28.8% | 27.9% | 27.7% | 31.3% |
| Gross profit | $4.0B | $3.6B | $3.4B | $3.7B |
| Operating income | $1.5B | $1.1B | $1.1B | $1.8B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Is Hims & Hers Stock Ready For A Longer Cash Burn?
2026-10-08 · What to Expect From Labcorp Holdings’ Q3 2026 Earnings Report
2026-10-08 · Leerink Partners Adjusts Labcorp Price Target to $365 From $350
2026-10-06 · Evercore ISI Adjusts Price Target on Labcorp Holdings to $330 From $340, Maintains Outperform Rating
2026-10-05 · 2 Volatile Stocks to Consider Right Now and 1 We Find Risky
2026-09-30 · DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?
2026-09-30 · Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
2026-09-29 · Is This the Right Time to Add Labcorp Stock to Your Portfolio?
2026-09-29 · 3 Low-Volatility Stocks That Concern Us
2026-09-23 · Labcorp Holdings (LH) Eyes Acquisitions And Lab Tech Investment After 2026 Investor Day
2026-09-23 · 2 Small-Cap Stocks to Research Further and 1 Facing Challenges
2026-09-23 · Is Labcorp Holdings Stock Outperforming the Dow?
Price (daily)
Full chart · RSI · MACD · patterns